Nvidia expanded its push into life sciences by announcing partnerships and co‑innovation investments with pharmaceutical and lab companies, including a five‑year, $1 billion collaboration with Eli Lilly. The deals, revealed during JPM, pair Nvidia’s computing and AI model expertise with Lilly’s drug discovery pipeline and Thermo Fisher’s laboratory infrastructure. Nvidia framed the partnerships as infrastructure plays: co‑innovation labs, compute investments and joint projects to integrate AI models with lab automation and drug discovery workflows. Lilly and Nvidia said the collaboration will build large‑scale data and model platforms to accelerate target selection and lead optimization. Industry participants said the moves signal a shift from proof‑of‑concept AI projects to industrialized, compute‑backed discovery platforms. For biopharma, the partnerships aim to reduce early‑stage bottlenecks by combining high‑performance computing, proprietary datasets and lab automation.